Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer

International Journal of Urology

Volumn 16, Issue 4, 2009, Pages 369-374

  Tambo, Mitsuhiro ^a   Higashihara, Eiji ^a   Terado, Yuichi ^a   Nutahara, Kikuo ^a   Okegawa, Takatsugu ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

Biochemical recurrence; HER2 neu; Prostate cancer

Indexed keywords

ANTIANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GONADORELIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 64549128211     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02253.x     Document Type: Article

References (18)

1. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999 5 : 280 5.
2. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: Molecular structure to molecular epidemiology. Crit. Rev. Oncog. 1994 5 : 313 29.
3. Arai Y, Yoshiki T, Yoshida O. C-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer. Prostate 1997 30 : 195 201.
4. Osman I, Mikhail M, Shuch B et al. Serum levels of shed HER2/neu protein in men with prostate cancer correlate with disease progression. J. Urol. 2005 174 : 2174 77.
5. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int. J. Urol. 2006 13 : 1197 201.
6. Nishio Y, Yamada Y, Kokubo H et al. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006 68 : 110 15.
7. Carless J, Lloreta J, Salido M et al. HER-2/neu expression in prostate cancer: A dynamic process?. Clin. Cancer Res. 2004 10 : 4742 45.
8. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen independence. Br. J. Cancer 2004 90 : 449 54.
9. Sim HG, Lau WKO, Cheng CWS. Predictors of androgen independence in metastatic prostate cancer. Br. J. Urol. 2004 93 : 1221 4.
10. Okegawa T, Noda H, Kato M, Miyata A, Nutahara K, Higashihara E. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 2000 44 : 210 18.
11. Taplin ME, George DJ, Halabi S et al. Prognostic significance of plasma chromogranin A levels in patients with hormone refractory prostate cancer treated in cancer and leukemia group B 9480 study. Urology 2005 66 : 386 91.
12. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2001 2 : 127 37.
13. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. The extracellular domain of the c-erbB-2 protein is released from tumor cells by proteolytic cleavage. Oncogene 1993 3 : 2917 23.
14. Rundhaug JE. Matrix metalloproteinases, angiogenesis and cancer. Clin. Cancer Res. 2003 9 : 551 4.
15. Lara PN Jr., Meyers FJ, Gray CR et al. HER2/neu is overexpressed infrequently in patients with prostate carcinoma: Results from the California cancer consortium screening trial. Cancer 2002 94 : 2584 9.
16. Tse C, Brault D, Gligorov J et al. Evaluation of the quantitative analysis methods real-time PCR for HER2 gene quantification and ELISA of serum HER2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER2 status in breast cancer patients. Clin. Chem. 2005 51 : 1093 101.
17. Ziada A, Barqawi A, Glode LM et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004 60 : 332 7.
18. de Bono JS, Bellmunt J, Attard G et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone refractory prostate cancer. J. Clin. Oncol. 2007 25 : 257 62.